John is Regius Professor of Medicine at Oxford University. His research interests are in autoimmune diseases and immunology, where he has contributed to our understanding of immune activation in autoimmune diseases. He served as President of the Academy of Medical Sciences from 2006 to 2011 and chaired the Office for the Strategic Coordination of Health Research until 2017. In 1993 he founded the Wellcome Trust Centre for Human Genetics. In 2001 he was appointed non-executive director of Roche Holding AG and in 2008 he joined the Gates Foundation Global Health Advisory Board, which he has chaired since 2012. In 2011 Sir John was appointed a UK Life Sciences Champions by the PM. He sits on the board of Genomics England Limited and chairs its Science Advisory Committee. He was knighted (GBE) in the 2015 New Year Honours for services to medicine, medical research and the life science industry.
Laura will be joined by Cecilia Chisholm, Mahesh Kudari and Marc Watson to talk about careers and career paths through pharmaceutical medicine.
We have three speakers who are giving their experiences of different roles within pharma, as a springboard for discussions for those who may be interested in exploring a different role.
- Clinical development
- Medical Affairs
Renata is a Pharmaceutical Development Specialist with 30 years’ experience in scientific development, regulatory approval and commercialisation of new medicines. She started her career in academic cardiovascular research at St Thomas’s Hospital, London, then joined Roche where she led teams developing key projects including Tamiflu for influenza, and Avastin for cancer. In 2015 Renata joined Cancer Research UK heading up Project and Portfolio management.
Renata is a trustee of PTEN Research Foundation, holds a number of Non-Executive Directorships and Scientific advisor roles, and is a member of the Policy and Communications Committee of the Faculty of Pharmaceutical Medicine.
Emma is Global Head of Medical Affairs at F2G Ltd, a UK and Austria based biotech where she is responsible for the global medical and commercial strategies for a novel antifungal drug for serious systemic infections, in clinical development. She has 20 years’ experience in the pharmaceutical industry and 10 years’ experience in antifungals. Her background is in internal medicine, undertaking her medical training at University College and the Middlesex School of Medicine, London.
Craig is an independent Pharmaceutical Physician with special interest in Medicines/Medical-Devices Benefit-Risk Management & Pharmacovigilance. He graduated MB BCh, MSc Med, PhD and held full-time academic/research posts until 1998. He then joined Pfizer R&D and in 2010-2019 was Vice President in Drug Safety at Pfizer, overseeing Safety Signal Detection/Evaluation and Benefit-Risk Management for 700+ products across the product drug lifecycle. He is an FPM Appraiser and a committee member for our Policy and Communications Group and member of our Government and Healthcare Policy Expert Group. He holds a GMC License to Practise Pharmaceutical Medicine.
Neil worked at GSK for 11 years, initially in Medical Affairs and subsequently as a Director in Respiratory Clinical Development. He was Project Physician Leader for a novel drug in asthma at GSK, before taking on new challenges as the Medical Director at Vectura – a clinical development company specialising in inhaled products for respiratory disease. Neil has an MSc in Pharmaceutical Medicine from Surrey University and he continues clinical practice as Honorary Clinical Fellow in Respiratory Medicine for a weekly hospital clinical session. He has contributed to a number of journals over the years, including Pharmaceutical Physician.
Gillies joined the pharmaceutical industry in 1986 and has spent 30 years in clinical development, medical management and commercial roles. He was Medical Director, UK and Northern Europe for Bristol-Myers Squibb 1996-2002, with responsibility for the clinical development of all BMS compounds in the UK and Northern Europe. Gillies then became VP and head of Clinical Development for GlaxoSmithKline Biologicals where he had global responsibility for the clinical development of GSK vaccines. From 2003 to 2009 he ran his own business providing clinical development and management consultancy to a broad range of R&D based pharmaceutical companies. In 2009 he became Chief Medical Officer of Algeta AS, a listed Norwegian biotech company developing a product for prostate cancer. Gillies sits on the Scientific Advisory Boards of a number of US and EU biotech companies, is a Board member of Clarity Pharmaceuticals in Australia, and is Chair of the FPM Policy and Communications Group.
Laura is the Neurometabolic Global Medical Director at Orchard Therapeutics, specialising in gene therapies for rare diseases. Since joining industry in 2015 from a surgical career, she has experienced roles in large pharma and biotech at the global, EU, and local affiliate levels. Her portfolios have ranged from primary care to ultra-orphan indications, and she has worked in both the UK and US. She is in her final year of PMST training and sits on the FPM trainees’ committee.
He is Director of Education & Training at the Faculty of Pharmaceutical Medicine & national Programme Director for pharmaceutical medicine specialty training for pharmaceutical & regulatory physicians in UK. He is a Board Member of the PharmaTrain Federation, developing & introducing internationally a platform of education & training for all in medicines development / clinical research: industry, academia, clinical trial investigators.
Peter was a founding Fellow of the Faculty of Pharmaceutical Medicine (FPM), Royal Colleges of Physicians UK (1989), & with others made a major contribution to achieving recognition & legal listing for the medical Specialty of Pharmaceutical Medicine in 2002.
Marcia is the Chief Executive of FPM. She was previously the Assistant Director for Research and Policy at the Royal College of Paediatrics and Child Health. She has a wealth of experience in research and policy development as well as project management, which she gained in both the public and private sectors.
Marcia sits on the Management Group Committee as well as the Inclusion and Diversity Committee of the Royal Society of Chemistry, is on the editorial board of the National Health Executive, a Trustee of a Multi-Academy Trust and is a passionate supporter for equal opportunities for all.
Tim is our President and a giant of our specialty. Whilst working as an NHS Consultant at Papworth Hospital, Cambridge he developed intravenous prostacyclin (the first therapy to improve survival in idiopathic Pulmonary Arterial Hypertension), as well as inhaled nitric oxide as a future treatment for neonatal pulmonary hypertension.
As Professor of Medicine, Sheffield University, he established the national network of accredited centres for the treatment of pulmonary hypertension, and led an international programme to construct the first “virtual lung” for the study of pharmacology of inhaled therapies. Later, as Corporate Clinical Director of Chiesi Farmaceutici, Tim began the development of the first triple inhaler for COPD, Trimbow. He is currently a scientific advisor to Akari Therapeutics Ltd and Camcon Ltd, where Tim is using his expertise to work on COVID-19 related therapies.